Internal Medicine, Hematology & Oncology · Scottsdale, AZ
NPI
1558534495
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
13400 E Shea Blvd
Scottsdale, AZ, 85259
Phone (480) 301-8000
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.7M
74,846 services
Medicare patients, 2024
612
Average age 74
Drug cost, 2024
$4.8M
917 prescriptions
Company payments, 2025
$3,143
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jeanne M Palmer was code J9144 (injection, daratumumab, 10 mg and hyaluronidase-fihj), 6,480 times for 32 patients. In total Jeanne M Palmer billed 74,846 services in 144 codes, and Medicare paid $1.7M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-09-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 6,480 | 32 | $39.64 | $257K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 6,400 | 27 | $43.47 | $278K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 4,050 | 25 | $0.11 | $452 |
| J9267 Injection, paclitaxel, 1 mg | Office | 2,646 | 11 | $0.08 | $212 |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 960 | 16 | $36.98 | $35K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 664 | 62 | $0.09 | $59.67 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 630 | 55 | $0.63 | $397 |
| J9041 Injection, bortezomib, 0.1 mg | Office | 520 | 12 | $1.33 | $690 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 392 | 42 | $0.07 | $28.77 |
| J0461 Injection, atropine sulfate, 0.01 mg | Office | 385 | 13 | $0.07 | $28.41 |
| 96375 Injection Administration | Office | 272 | 118 | $11.78 | $3,203 |
| 99214 Office E&M - Established | Office | 225 | 149 | $92.08 | $21K |
| 96413 Chemotherapy Administration | Office | 208 | 179 | $96.31 | $20K |
| J9206 Injection, irinotecan, 20 mg | Office | 188 | 13 | $1.95 | $367 |
| 99233 Hospital E&M - Subsequent | Facility | 173 | 34 | $90.95 | $16K |
By year: 2022 $1.3M for 64,906 services; 2023 $1.2M for 57,961 services; 2024 $1.7M for 74,846 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jeanne M Palmer prescribed most often to Medicare patients was Jakafi (Ruxolitinib Phosphate), with 164 prescriptions and refills. In total Jeanne M Palmer wrote 917 Medicare prescriptions that cost $4.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | 164 | 172 | 34 | $2.9M |
| Acyclovir Generic | 87 | 143 | 23 | $1,527 |
| Pegasys Peginterferon Alfa-2a | 54 | 54 | Under 11 | $244K |
| Eliquis Apixaban | 45 | 55 | Under 11 | $31K |
| Fluconazole Generic | 41 | 44 | 14 | $1,772 |
| Allopurinol Generic | 32 | 70 | Under 11 | $159 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 31 | 46 | Under 11 | $128 |
| Gabapentin Generic | 25 | 35 | Under 11 | $211 |
| Besremi Ropeginterferon Alfa-2b-Njft | 25 | 25 | Under 11 | $414K |
| Hydroxyurea Generic | 20 | 44 | Under 11 | $315 |
| Hydrocortisone Generic | 16 | 32 | Under 11 | $759 |
| Warfarin Sodium Generic | 15 | 28 | Under 11 | $145 |
| Imatinib Mesylate Generic | 15 | 16 | Under 11 | $1,624 |
| Levofloxacin Generic | 14 | 14 | 11 | $194 |
| Ojjaara Momelotinib Dihydrochloride | 13 | 17 | Under 11 | $457K |
Brand drugs: 370 claims; generic drugs: 547 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jeanne M Palmer $3,143 ($3,143 in general payments such as food, travel and fees) from 6 companies. The largest payer was Incyte Corporation with $2,865.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.